GENE ONLINE|News &
Opinion
Blog

Eli Lilly
Innovation Eli Lilly
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
In-Depth Weight lossmarket insights
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
Trending PartnershipsAI
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Ranking & Reports market insightsViking Therapeutics
Viking Therapeutics Ready to Make Billions as a Strong Contender in the GLP-1 Weight Loss Space
2024-08-29
Asia-Pacific Weight lossTirzepatide
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
R&D Alzheimer's Disease
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
Trials & Approvals Alzheimer's DiseaseFDA Approved
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
Deals Eli LillyAI
Eli Lilly and OpenAI Team Up to Combat Drug-Resistant Pathogens
2024-07-02
Manufacturing Market
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
2024-05-27
Trending Weight loss
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
Partnerships OncologyRadiopharmaceutical
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Ranking & Reports Eli LillyQ1 Report
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
In-Depth LawsuitEli LillyNovo Nordisk
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Editors' Picks LiraglutideObesitySemaglutideTirzepatide
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)
2024-03-07
Editors' Picks ObesityEli LillyNovo NordiskTirzepatideSemaglutideLiraglutideNaltrexonebupropion
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (First Part)
2024-02-15
1 2 3 … 5
LATEST
Bio Japan 2024 and Medical Japan 2024 Unleashing Innovation in Biopharmaceuticals and Healthcare Technologies
2024-10-07
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
How TCELS is Moving Thailand’s Biotech Industries From Local to Global
2024-10-04
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
READ MORE
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-10
BioJapan / Regenerative Medicine Japan / healthTECH JAPAN 2024
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top